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Objective: During lung transplantation, cells in the pulmonary parenchyma are sub-
jected to ischemia, hypothermic storage, and reperfusion injury. Platelets, whose
granular contents include adhesion receptors, chemokines, and coactivating sub-
stances that activate inflammatory and coagulant cascades, likely play a critical role
in the lung allograft response to ischemia and reperfusion. The platelet response to
the pulmonary allograft, however, has never been studied. Here we report significant
platelet activation immediately after lung transplantation.
Methods: We performed a prospective cohort study comparing markers of platelet
activation in patients undergoing lung transplantation and patients undergoing non-
transplant thoracotomy. Plasma levels of soluble P-selectin, soluble CD40 ligand,
and platelet–leukocyte conjugates were measured before surgery, after skin closure,
and at 6 postoperative hours.
Results: Both soluble P-selectin and soluble CD40 ligand levels increased signifi-
cantly after lung transplantation but not after thoracotomy. Additionally, platelet–
monocyte conjugate fluorescence was significantly higher after lung transplantation
than after thoracotomy alone.
Conclusion: These findings suggest that platelet activation is significantly increased
after lung transplantation beyond that expected from the postoperative state. The
increase in circulating platelet–monocyte conjugates suggests an important interac-
tion between platelets and inflammatory cells. Further research should examine
whether platelet activation affects early graft function after lung transplantation.
L
ung transplantation has emerged as a successful surgical therapy for end-stage
pulmonary disease.1 The lung is the most richly vascular transplanted organ,
and each milliliter of blood coursing through the transplanted lungs often con-
tains more than 300,000 platelets. Platelets contain potent thrombotic and vasoactive
compounds and mediate key pathways in inflammation. To our knowledge, however,
the platelet response to lung transplantation has not been previously studied in human
beings.
Platelets adhere to activated endothelium, crosslinking leukocytes to injured endo-
thelial surfaces.2 Platelet-mediated leukocyte adherence, diapedesis, and infiltration
of the lung allografts are integral to early graft failure after lung transplantation. Sev-
eral biomarkers with potential physiologic significance reflect in vivo platelet activity.
P-selectin (CD62P) is a 140-kDa transmembrane protein that is stored in the alpha and
dense granules of platelets and in endothelial cells; this protein is expressed on the cell
surface, and some is shed during degranulation (soluble P-selectin [sP-selectin]).3
sP-selectin binds P-selectin glycoprotein ligand-1 on leukocytes, arresting them in
transit and upregulating inflammation at the blood–tissue interface.4 CD40 ligand
(CD154) is a trimeric transmembrane protein that also mobilizes to the cell surface
of the activated platelet before being shed (soluble CD40 ligand [sCD40L]).5,6 As
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sCD40L 5 soluble CD40 ligand
sP-selectin 5 soluble P-selectin
the cognate interaction between CD154 and CD40 (on endo-
thelial and other cells) can contribute not only to immune cell
coactivation but also platelet clumping, this interaction is
likely important in the context of lung ischemia and reperfu-
sion.5 Platelets produce more than 95% of all sCD40L, which
stimulates cyclooxygenase-2 and prostaglandin E2 synthesis,
leading to inflammation.7,8 Further, circulating platelet–
leukocyte conjugates, as assessed by flow cytometry, are con-
sidered to be a sensitive marker of the complex interactions
that occur between platelet activation and inflammation path-
ways in vivo.9
Because platelets play a key role in the recruitment and
binding of leukocytes to vascular sites of inflammation,
platelet activation could be an integral component of early
inflammatory and thrombotic processes in the reperfused
lung allograft. The effects of lung transplantation on
sP-selectin, sCD40L, and circulating platelet–leukocyte
conjugates are, however, unknown. We therefore aimed to
determine whether platelet activation is increased after
lung transplantation. We hypothesized that sP-selectin,
sCD40L, and circulating platelet–leukocyte conjugates
would be increased in patients undergoing lung transplanta-
tion relative to patients undergoing other types of thoracic
surgery.
Materials and Methods
Study Design and Subjects
We performed a prospective cohort study of patients undergoing
lung transplantation and patients undergoing nontransplant thora-
cotomy. Patients with a known history of platelet disorders or recent
antiplatelet medication use, including aspirin or ticlopidine, were
excluded from study. Patients with planned cardiopulmonary by-
pass or a history of chemotherapy or radiation therapy to the chest
were also excluded, because platelet reactivity is altered by cardio-
pulmonary bypass and advanced malignancy.10,11 All patients in
this study underwent preoperative induction of immunosuppression
with tacrolimus (0.04 mg/kg), azathioprine (2 mg/kg), methylpred-
nisolone (1 g), and basiliximab (20 mg).
Blood Sampling
After informed consent was obtained, blood sampling was per-
formed (1) before induction of anesthesia and immunosuppression,
(2) immediately postoperatively, after skin closure, and (3) 6 hours
later. Clinical data, including platelet counts, were recorded. Phle-
botomy was performed through a fresh needle stick at each point
with a 21-gauge butterfly into Vacutainer tubes (BD, Franklin
Lakes, NJ) containing EDTA. Whole blood was spun at 7000g for
15 minutes, and plasma was frozen at 280C until batch analysis.
All blood samples were processed within 15minutes of phlebotomy.680 The Journal of Thoracic and Cardiovascular Surgery c MaPlasma sP-selectin and sCD40L levels were measured in tripli-
cate with commercially available assays (R&D Systems, Minneap-
olis, Minn) according to the manufacturer protocol.
Platelet–Leukocyte Conjugates
Circulating platelet–leukocyte conjugates were quantified by flow
cytometry, as previously described.2,12,13 Briefly, 200 mL whole
blood was used from each sample for analysis. Three samples
were run in parallel: a negative control, an unstimulated sample,
and 10-mmol/L adenosine diphosphate–stimulated sample. The
samples were labeled sequentially with phycoerythrin-labeled anti-
human platelet CD42 antibody (BD) and then fluorescein isothio-
cyanate–labeled antihuman leukocyte CD14 antibody (BD). After
labeling, all samples were fixed and then lysed with Optilyse solu-
tion (Beckman Coulter, Inc, Fullerton, Calif) according to manufac-
turer protocol. All tubes were then immediately analyzed on
a FACSCalibur Flow Cytometer (BD) according to the method of
Michelson with Cell Quest Pro software.14 Isotype-matched fluores-
cein isothiocyanate–labeled IgG (BD) served as negative control
preparations. Particles expressing both CD42 and CD14 were iden-
tified as platelet–leukocyte conjugates and then further subdivided
into either platelet–monocyte or platelet–neutrophil conjugates. Dif-
ferences in granularity and the intensity of CD14 expression allowed
differentiation between monocyte and neutrophil populations.2,12,13
Measures of conjugates were expressed as the mean intensity of
phycoerythrin-labeled CD42 per particle, reflecting the number of
platelets bound per monocyte-neutrophil conjugate, and as the per-
centage of the particles positive for phycoerythrin-labeled CD42 and
fluorescein isothiocyanate–labeled CD14. Flow cytometric platelet–
leukocyte conjugate data are presented as fractional change from
baseline.
Statistical Analysis
Continuous variables are summarized with mean 6 SE or median
with interquartile range, as appropriate. Comparison of preopera-
tive with postoperative plasma biomarkers and flow cytometric re-
sults was performed with signed rank tests. We compared patients
undergoing lung transplantation with those undergoing thoracot-
omy alone at each postoperative time point with Mann–Whitney
U tests. Multivariate linear regression was also performed for post-
operative plasma biomarker levels with adjustment for baseline
levels.
Before the study, we performed power analyses that indicated
that a sample size of 7 patients undergoing transplantation and
10 control patients would provide 80% power (a 5 .05) to detect
a difference between the groups of 1.5 SD, the effect size seen in pre-
vious studies of platelet activation.15-17 Statistical analyses were
performed using Analyze-it! (Analyse-it Software, Ltd, Leeds,
UK) and STATA (Stata Corporation, College Station, Tex) software
packages.
Ethical Guidelines
This study was approved by theWestern Institutional Review Board
(Nov 16, 2004, WIRB Protocol No. 2198). All patients voluntarily
participated after signing a consent form before the scheduling of
their surgery. There were no patient exposures to any dangerous
chemical or toxic substance. Funding agencies did not participate
in data analysis or manuscript preparation.rch 2008
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Study Population
Twenty-six patients were enrolled between March and Au-
gust 2005. Ten patients were enrolled in the lung transplant
study group; 3 were subsequently excluded because of un-
planned cardiopulmonary bypass. Four patients underwent
bilateral transplantation. The indications for transplantation
were pulmonary fibrosis (n 5 5) and cystic fibrosis (n 5 2).
Sixteen patients were recruited into the reference thoracot-
omy group; 6 were excluded intraoperatively after the proce-
dure was aborted because of advanced malignancy. The
indications for thoracotomy in the final reference group
were cancer (n 5 9) and thymic cyst (n 5 1). Lobectomy
was performed in 7 cases, thymectomy in 1, and pleurodesis
in 2, after formal resection was abandoned because of unex-
pected advanced malignancy. The final study population
comprised 7 patients who underwent lung transplantation
and 10 patients who underwent nontransplant thoracotomy
(Table 1).
sP-Selectin Levels
Baseline pre-operative sP-selectin levels in the lung trans-
plant group were similar to those in the thoracotomy group
(Figure 1). Significant increases in sP-selectin levels were
seen in the lung transplant group at both the postoperative
and 6-hour times relative to baseline (P , .05), however,
no change in sP-selectin was observed in the thoracotomy
group. Mean sP-selectin levels were significantly higher in
the lung transplant group than in the thoracotomy group dur-
ing the immediate postoperative period (59 vs 33 pg/mL, P5
.03) and at 6 hours (104 vs 40 pg/mL, P 5 .001).
Higher sP-selectin levels immediately after lung trans-
plantation were associated with a greater decrease in platelet
count on routine phlebotomy from baseline to postoperative
day 1 (P 5 .006) and day 2 (P50.002). Similar associations
TABLE 1. Patient characteristics of the lung transplant and
thoracotomy groups
Transplant (n 5 7) Thoracotomy (n 5 10)
Age (y, mean 6 SD) 51 6 16 59 6 13
Sex (% male) 57% 70%
Transplant type
(% bilateral)
57% —
Ischemia time (min)
First lung 180 —
Second lung (n 5 4) 247 —
Lung resection — 70%
Platelets (103 cells/cm3,
mean 6 SE)
Preoperative 365 6 174 221 6 48
Day 1 205 6 114 194 6 69
Day 2 159 6 83 183 6 61
Day 3 160 6 83 184 6 64The Journal of Thobetween the 6-hour postoperative sP-selectin level and
changes in platelet counts at days 1 and 2 were shown,
although these were not statistically significant (P 5 .10
and P 5 .06, respectively).
sCD40L Levels
Mean sCD40L levels were similar between the lung trans-
plant and thoracotomy groups at baseline (481 vs 524 ng/
mL, P 5 .53; Figure 2). The lung transplant group demon-
strated a significant increase in sCD40L at the 6-hour point
relative to the baseline value (P, .05), whereas no difference
was observed in the control group. sCD40L levels were
Figure 1. sP-selectin levels before surgery (Pre-Op), immediately
after surgery (Post-Op), and 6 hours later (6Hr). Asterisk indicates
P < .05.
Figure 2. SCD40L levels before surgery (Pre-Op), immediately
after surgery (Post-Op), and 6 hours later (6Hr). Asterisk indicates
P < .05.racic and Cardiovascular Surgery c Volume 135, Number 3 681
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after skin closure (577 vs 524 ng/mL, p5 0.08), but this dif-
ference did not reach statistical significance. sCD40L levels
at the 6-hour time point were significantly higher in the
lung transplant recipients than in the control group (815 vs
547 ng/mL, P 5 .022).
Immediately after lung transplantation, higher sCD40L
levels were associated with a decrease in platelet count on
postoperative day 1 or 2 (P 5 .058 and P 5 .05, respec-
tively). There were no associations between sCD40L levels
at 6 hours and the change in platelet count on days 1 or 2
(P . .50 for both).
Circulating Platelet–Leukocyte Conjugates
Figure 3 shows platelet–monocyte conjugates, expressed as
the median (with interquartile range) fluorescent intensity
of platelets per conjugate. No differences in the fluorescent
intensity of platelets per platelet–monocyte conjugate were
observed at the preoperative point, nor in the immediate post-
operative period (P5 .55). A significant increase in the fluo-
rescent intensity of platelets per conjugate from baseline,
however, was seen at 6 postoperative hours in transplant re-
cipients relative to thoracotomy patients (P5 .02). No differ-
ences in the percentage of monocytes engaged in circulating
platelet–monocyte conjugates were observed between lung
transplant and thoracotomy groups (Figure 4). Also, no dif-
ferences were seen between patient groups in the fluorescent
intensity of platelets per platelet–neutrophil conjugate or in
the percentage of neutrophils with bound platelets (data not
shown).
Discussion
To our knowledge, this is the first study to measure platelet
activation before and after human lung transplantation.682 The Journal of Thoracic and Cardiovascular Surgery c MaAlthough any surgical procedure might be expected to result
in systemic platelet activation, we have shown that sP-selec-
tin, sCD40L, and platelet–monocyte conjugates increase af-
ter lung transplantation to a greater degree than after other
types of thoracic surgery. This implies that platelet activation
is particularly pronounced after lung transplantation, which
could modulate graft function or failure after transplantation.
Previous studies have demonstrated pulmonary platelet
deposition 24 hours after lung transplantation in dogs.18
Platelet deposition has also been reported during reperfusion
injury of rat and human lungs.19-21 In a rat model of lung
transplantation, platelet accumulation was shown to contrib-
ute to postischemic graft dysfunction.22 Okada and co-
workers23 reported that treatment with a prostacyclin
analog with antiplatelet activity attenuated reperfusion injury
by abrogating platelet sequestration in rat lung grafts.23 In
addition, antiplatelet agents attenuate hyperacute xenograft
failure.24
We presume that the site of platelet release of sP-selectin
and sCD40L and monocyte interaction is the newly reper-
fused pulmonary vascular bed. Evidence suggests that leuko-
cyte activation, adhesion, and infiltration are integral to the
development of ischemia–reperfusion injury after lung trans-
plantation.25,26 P-selectin binding is an important element of
this process, as evidenced by the reduction of lung injury with
P-selectin blockade at the time of reperfusion.27 Further,
there is strong link between CD154/CD40 interaction and in-
terleukin 8 upregulation, which also happens to be associated
with poorer graft function.28,29 The results of these studies, in
combination with our findings, suggest an important role of
platelets in mediating ischemia–reperfusion injury after
lung transplantation. Future studies should focus on the rela-
tionships among platelet activation, the risk of ischemia–
reperfusion injury, and clinical outcomes after lungFigure 3. Platelet-monocyte conjugate fluores-
cence before surgery (Pre-Transplant), immedi-
ately after surgery (Post Op), and 6 hours later
(6 Hrs Post Op). Asterisk indicates P < .05.rch 2008
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venting or treating ischemia–reperfusion injury and primary
graft dysfunction, which currently have no specific medical
therapy, in lung transplant recipients.
Although the number of platelets bound per monocyte
conjugate increased after lung transplantation, we were un-
able to detect an increased percentage of monocytes with
bound platelets. A possible explanation for this finding is
that there may be a rapid sequestration of activated platelets
in the lung allograft, as previously described,20,21,23 limiting
the number of platelets that would interact with circulating
monocytes. We suggest that this could occur to a greater ex-
tent in lung than in other solid organ transplantation because
of the large surface area of dysfunctional endothelium. In ad-
dition, the low-pressure pulmonary circulation may facilitate
platelet endothelial binding, as previous histologic studies of
fresh lung allografts have shown the deposition of platelets in
the lungs early after reperfusion.20
There are several possible limitations of this study. First,
endothelial release of sP-selectin or sCD40L could account
for the findings in our study. The vast majority of sCD40L
is platelet-derived, however, and it is, therefore, a highly spe-
cific marker of platelet activation.7 Second, biomarker analy-
sis was performed at two time points after transplantation; we
cannot exclude the possibility that assessment after reper-
fusion might show even more substantial differences. Third,
the sample size was small; however, we detected differences
consistent with our hypothesis, likely attributable to the pro-
spective planning and sample size calculations based on pre-
vious work. It should be noted that this is the first direct study
of platelet activation after human lung transplantation, as
well as the first study to use the sensitive techniques
afforded by flow cytometry to examine platelet–leukocyte
conjugates directly. Fourth, we did not investigate the associ-
ation between platelet biomarkers and indicators of graft
function (eg, ratio of PaO2 to inspired oxygen fraction).
Figure 4. Fractional change from baseline in platelet–monocyte
conjugate formation immediately after surgery (Post) and 6 hours
later (6 Hrs). Asterisk indicates P < .05.The Journal of ThorLarger, multicenter studies will be necessary to study
whether indicators of platelet activation correspond to such
clinical indices. Fifth, all lung transplant recipients received
preoperative induction of immunosuppression before trans-
plantation, and the possibility of interactions of these phar-
macologic agents with platelets has not been studied.
In summary, this study shows that sP-selectin, sCD40L,
and platelet–leukocyte interactions are significantly in-
creased after human lung transplantation but not after thora-
cotomy alone. Future studies should attempt to replicate our
findings and focus on the relationship to clinical markers of
reperfusion injury with sP-selectin, sCD40L, and platelet–
leukocyte conjugate formation. Abrogation of the platelet
activation and adhesion cascades in lung transplantation
may offer a future clinical avenue to decrease the impact of
reperfusion injury.
References
1. Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: opportuni-
ties for research and clinical advancement. Am J Respir Crit Care
Med. 2005;172:944-55.
2. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA,
Lessard DM, et al. Circulating monocyte-platelet aggregates are an early
marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:
1002-6.
3. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and
cardiovascular disease. Eur Heart J. 2003;24:2166-79.
4. Asa D, Raycroft L, Ma L, Aeed PA, Kaytes PS, Elhammer AP, et al. The
P-selectin glycoprotein ligand functions as a common human leukocyte
ligand for P- and E-selectins. J Biol Chem. 1995;270:11662-70.
5. Henn V, Slupsky JR, Gra¨fe M, Anagnostopoulos I, Fo¨rster R, Mu¨ller-
Berghaus G, et al. CD40 ligand on activated platelets triggers an inflam-
matory reaction of endothelial cells. Nature. 1998;591-4.
6. Henn V, Steinbach S, Bu¨chner K, Presek P, Kroczek RA. The inflamma-
tory action of CD40 ligand (CD154) expressed on activated human
platelets is temporally limited by coexpressed CD40. Blood. 2001;98:
1047-54.
7. Andre´ P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived
CD40L: the switch-hitting player of cardiovascular disease. Circulation.
2002;106:896-9.
8. Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP. An associa-
tion of soluble CD40 ligand (CD154) with adverse reactions to platelet
transfusions. Transfusion. 2006;46:1813-21.
9. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for
circulating platelet-leucocyte aggregates. Br J Haematol. 1997;99:
808-16.
10. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass.
Ann Thorac Surg. 1998;66:2145-52.
11. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interac-
tions: mechanisms and pharmacology of tumour cell–induced platelet
aggregation. Br J Pharmacol. 2004;143:819-26.
12. Xiao Z, The´roux P. Clopidogrel inhibits platelet-leukocyte interactions
and thrombin receptor agonist peptide-induced platelet activation in pa-
tients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43:
1982-8.
13. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Lo¨sche W. The
GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leuko-
cyte interaction and tissue factor expression following platelet activation
in whole blood in vitro. Platelets. 2002;13(7):401-6.
14. Linden MD, Frelinger AL 3rd, Barnard MR, Przyklenk K, Furman MI,
Michelson AD. Application of flow cytometry to platelet disorders.
Semin Thromb Hemost. 2004;5:501-11.
15. Vanacore R, Guida C, Urciuoli P, Mazzoni A, Bianco I, Urbani L, et al.
High levels of circulating monocyte-platelet aggregates can predictacic and Cardiovascular Surgery c Volume 135, Number 3 683
Cardiothoracic Transplantation Sternberg et al
TXrejection episodes after orthotopic liver transplantation. Transplant
Proc. 2003;35:1019.
16. Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation
and modulation of adhesion receptors in pediatric patients with congen-
ital heart disease undergoing cardiopulmonary bypass. J Thorac Cardi-
ovasc Surg. 1994;107:280-8.
17. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Car-
diopulmonary bypass induces leukocyte-platelet adhesion. Blood. 1992;
79:1201-5.
18. Hoyer J, Lebreuil G, Sicardi F, Noirclerc M. Effects of experimental
lung transplantation on blood coagulation and platelets. Eur Surg Res.
1974;6:110-6.
19. Okada Y, Marchevsky AM, Zuo XJ, Pass JA, Kass RM, Matloff JM,
et al. Accumulation of platelets in rat syngeneic lung transplants: a poten-
tial factor responsible for preservation-reperfusion injury. Transplanta-
tion. 1997;64:801-6.
20. Colombat M, Castier Y, Lese`che G, Rufat P, Mal H, Thabut G, et al.
Early expression of adhesion molecules after lung transplantation:
evidence for a role of aggregated P-selectin-positive platelets in human
primary graft failure. J Heart Lung Transplant. 2004;23:1087-92.
21. Zenati M YS, Dowling RD, Stein KL, Griffith BP. Zenati M, Yousem
SA, Dowling RD, Stein KL, Griffith BP. Transplantation.
1990;50:165-7.
22. Naka Y, Chowdhury NC, Liao H, Roy DK, Oz MC, Michler RE, et al.
Enhanced preservation of orthotopically transplanted rat lungs by nitro-684 The Journal of Thoracic and Cardiovascular Surgery c Marglycerin but not hydralazine. Requirement for graft vascular homeostasis
beyond harvest vasodilation. Circ Res. 1995;76:900-6.
23. Okada Y, Marchevsky AM, Kass RM, Matloff JM, Jordan SC. A stable
prostacyclin analog, beraprost sodium, attenuates platelet accumulation
and preservation-reperfusion injury of isografts in a rat model of lung
transplantation. Transplantation. 1998;66:1132-6.
24. Pfeiffer S, Zorn GL 3rd, Zhang JP, Giorgio TD, Robson SC,
Azimzadeh AM, et al. Hyperacute lung rejection in the pig-to-human
model. III. Platelet receptor inhibitors synergistically modulate comple-
ment activation and lung injury. Transplantation. 2003;75:953-9.
25. de Perrot M, Young K, Imai Y, Liu M, Waddell TK, Fischer S, et al. Re-
cipient T cells mediate reperfusion injury after lung transplantation in the
rat. J Immunol. 2003;171:4995-5002.
26. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-
nduced lung injury. Am J Respir Crit Care Med. 2003;167:490-511.
27. Naka Y, Toda K, KayanoK, OzMC, Pinsky DJ. Failure to express the P-
selectin gene or P-selectin blockade confers early pulmonary protection
after lung ischemia or transplantation. Proc Natl Acad Sci U S A. 1997;
94:757-61.
28. De Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, et al.
Interleukin-8 release during early reperfusion predicts graft function in
human lung transplantation. Am J Respir Crit Care Med. 2002;165:
211-5.
29. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y,
Matsushima K. Prevention of lung reperfusion injury in rabbits by
a monoclonal antibody against interleukin-8. Nature. 1993;365:654-7.ch 2008
